Compass Therapeutics to Host Webcast Highlighting Top-Line Clinical Data from the Ongoing Randomized Phase 2/3 Study Evaluating Tovecimig in Patients with Biliary Tract Cancer

Rhea-AI Summary

Compass Therapeutics (Nasdaq: CMPX) has announced a webcast scheduled for April 1, 2025, at 8:00 AM ET to present top-line clinical data from their ongoing Phase 2/3 COMPANION-002 trial. The study evaluates tovecimig, a DLL4 x VEGF-A bispecific antibody, in combination with paclitaxel for treating patients with advanced biliary tract cancer (BTC).

The virtual event will be accessible via webcast, with a replay available for 90 days on Compass' Events page.

• Webcast scheduled for Tuesday, April 1, 2025 at 8:00 AM ET.
  

BOSTON, March 31, 2025 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, announced it will host a webcast on Tuesday, April 1, 2025 at 8:00 AM ET to review top-line clinical data from its ongoing Phase 2/3 COMPANION-002 clinical trial assessing tovecimig (a DLL4 x VEGF-A bispecific antibody) in combination with paclitaxel in patients with advanced biliary tract cancer (BTC). 

Webinar Details:

Date: Tuesday, April 1, 2025

Time: 8 AM EDT

Webcast: https://viavid.webcasts.com/starthere.jsp?ei=1712286&tp_key=3b05c5ebcd

Virtual/Replay availability: A replay will be archived for 90 days on Compass’ Events page.

About Compass Therapeutics
Compass Therapeutics, Inc. is a clinical-stage oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. Compass’s scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth. The company pipeline of novel product candidates is designed to target multiple critical biological pathways required for an effective anti-tumor response. These include modulation of the microvasculature via angiogenesis-targeted agents, induction of a potent immune response via activators on effector cells in the tumor microenvironment, and alleviation of immunosuppressive mechanisms used by tumors to evade immune surveillance. Compass plans to advance its product candidates through clinical development as both standalone therapies and in combination with proprietary pipeline antibodies based on supportive clinical and nonclinical data. The company was founded in 2014 and is headquartered in Boston, Massachusetts. For more information, visit the Compass Therapeutics website at https://www.compasstherapeutics.com.

Investor Contact
ir@compasstherapeutics.com

Media Contact
Anna Gifford, Chief of Staff
media@compasstherapeutics.com
617-500-8099

FAQ

What clinical trial data will Compass Therapeutics (CMPX) present on April 1, 2025?

CMPX will present top-line data from the Phase 2/3 COMPANION-002 trial evaluating tovecimig plus paclitaxel in advanced biliary tract cancer patients.

What is tovecimig and how is it being tested in the CMPX COMPANION-002 trial?

Tovecimig is a DLL4 x VEGF-A bispecific antibody being tested in combination with paclitaxel for advanced biliary tract cancer treatment.

How can investors access the CMPX clinical data webcast on April 1?

Investors can access the webcast at 8:00 AM ET via https://viavid.webcasts.com/starthere.jsp?ei=1712286&tp_key=3b05c5ebcd

How long will the CMPX tovecimig clinical data presentation replay be available?

The webcast replay will be archived for 90 days on Compass Therapeutics' Events page.